Janssen Enters into a License and Collaboration Agreement with F-star to Develop and Commercialize Multiple Bispecific Antibody Therapeutics
Shots:
- F-star to receive $17.5M up front and is eligible to receive ~$1.35B as near-term fees & milestones along with royalties on net sales of the product
- Janssen to get an exclusive royalty-bearing license globally to research- develop & commercialize up to 5 novels bispecific Abs directed to Janssen therapeutic targets using F-star’s Fcab and mAb2 platforms & will lead all research- development- and commercialization activities
- F-star's platform allows changes in the Fc region of a natural Ab to generate 2 additional distinct Ag binding sites. Fcab building blocks can be inserted into a natural IgG Ab to develop tetravalent mAb2 bispecific Abs that bind to two different Ag
Ref: F-star | Image: Janssen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com